COMy 2017 | How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau, MD, from the University Hospital of Nantes, Nantes, France, discusses the use of monoclonal antibodies in the treatment of myeloma at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Daratumumab is typically used in patients with advanced, end stage disease, with a response rate of approximately 30%. It has also been found to be effective in improving both overall and progression free survival in patients who have not responded to all other drugs currently available. Dr Moreau describes the promising results of daratumumab in both the POLLUX (NCT02076009) and CASTOR (NCT02136134). Other monoclonal antibodies are being developed, such as isatuximab, as well as other CD38 antibodies. There is hope for these antibodies to be approved for use earlier in the disease, to improve survival.
Get great new content delivered to your inboxSign up